Roquefort Therapeutics

(ROQ)
Sector: Open End and Miscellaneous Investment Vehicles
3.93p
-0.37p -8.53
Last updated: 12:05:11

Share information

Name Roquefort Therapeutics
Epic ROQ
Isin GB00BMDQ2T15
Industry Open End and Miscellaneous Investment Vehicles

Key numbers

Latest share price 3.93p Net gearing n/a
Market capitalisation £5.34 Debt ratio n/a
Shares in issue 129.15 Debt-to-equity ratio n/a
P/E ratio n/a Assets / equity ratio n/a
Total dividends per share n/a Price to book value n/a
Dividend yield n/a ROCE -76.19
Dividend cover n/a EPS growth n/a
Earning per share -1.56 52-week high / low 3.35p / 9.25p

Dividends

Type Ex-date Pay-date Net-dividend
No dividends declared

Contact details

Company name Roquefort Therapeutics
Address Eccleston Yards, 25 Eccleston Place, London, United Kingdom, SW1W 9NF
Telephone +44 (0)20 3290 9339
Website http://www.roquefortinvest.com/

Directors

Director Position
Mr Dr Darrin Disley Non-Executive Director
Dr Simon Sinclair Non-Executive Director
Ms Jean Duvall Non-Executive Director
Mr Stephen Paul West Executive Chairman
Mr Trevor Ajanthan (Ajan) Reginald Chief Executive Officer
Dr Michael Stein Independent Non-Executive Director
Mr Professor Sir Martin Evans Chief Scientific Officer

Company financials

Assets £ (m) 2022 2021
Reporting date 31/12/22 31/12/21
Intangible asssets and goodwill 5.34 1.48
Investments and other non-current assets n/a n/a
Total non-current assets 5.34 1.48
Inventory / work in progress n/a n/a
Trade and other receivables 0.1 2.18
Cash and equivalents 2.32 0.9
Other current assets and asset held for resale n/a n/a
Total of all assets 7.77 4.56
Liabilities £ (m) 2022 2021
Short term liabilities 0.28 0.2
Long term liabilities 0.28 0.28
Other liabilites / pension etc n/a n/a
Total of all liabilities 0.56 0.48
Net assets £ (m) 2022 2021
Net assets 7.21 4.08
Equity £ (m) 2022 2021
Share capital 1.29 0.72
Minority interests n/a n/a
Retained earnings -2.55 -0.91
Share premium account 4.4 3.46
Total equity 7.21 4.08
Income £ (m) 2022 2021
Turnover n/a n/a
Operating profit -1.63 -0.92
Pre-tax profit -1.63 -0.92